MedNet Solutions Announces Latest Release Of Its Award-Winning iMedNet eClinical Solution
Systemwide Enhancements Deliver Exceptional Configurability, Performance and Efficiency
MedNet Solutions, a global life sciences technology company specializing in clinical study management systems, is proud to announce the latest release of iMedNet™ eClinical, its innovative, cloud-based technology platform. iMedNet provides an extremely intuitive, flexible and affordable software-as-a-service (SaaS) solution – ideal for clinical trial sponsors and CROs wishing to quickly and efficiently build studies themselves.
"This iMedNet release delivers significant new and enhanced functionality throughout the system, encompassing our easy-to-use forms designer and randomization modules, as well as our casebook manager and robust reporting toolsets," remarked M. Clareece West, Chief Operating Officer of MedNet Solutions. "At MedNet, we're dedicated to continually refining our eClinical technologies to ensure we always deliver fully compliant and validated best-in-class solutions. Our most recent iMedNet release is tangible proof of that promise to our customers."
"We're incredibly excited about the latest iMedNet release," stated John M. (Rob) Robertson, President and CEO of MedNet Solutions. "It takes our iMedNet platform to the next level in terms of convenience, speed and control, not only for our customers, but for everyone involved in the clinical research initiative. And we're not stopping there; we're working on more exciting new functionality that will be rolled out early this coming summer. Stay tuned."
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
